Medical Design and Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • Subscribe to Print Magazine
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech

For the Treatment of Rheumatoid Arthritis, Surveyed European Rheumatologists Expect Well-Established TNF-Alpha Inhibitors to Lose Considerable Patient Share to Newer Agents in…

October 14, 2010 By Bio-Medicine.Org

BURLINGTON, Mass., Oct. 14 /PRNewswire/ — Decision Resources,
one of the world’s leading research and advisory firms for
pharmaceutical and healthcare issues, finds that, between 2010 and
2013, surveyed European rheumatologists expect well-established
TNF-alpha inhibitors to lose considerable patient share to newer
agents in this drug class, most notably Centocor Ortho
Biotech/Merck/Mitsubishi Tanabe/Janssen’s Simponi and UCB/Otsuka’s
Cimzia. The increased use of newer agents such as Simponi and
Cimzia will most likely occur in newly diagnosed patients and/or in
patients who do not respond to initial treatment with a biologic
agent.

The new European Physician & Payer Forum report entitled
Rheumatoid Arthritis in Europe: How Are Physicians and Payers
Responding to an Expanding Arsenal of Biologic Agents?
finds
that the well-entrenched TNF-alpha inhibitors that stand to lose
patient share include Amgen/Pfizer/Takeda’s Enbrel, Abbott/Eisai’s
Humira and Centocor Ortho Biotech/Merck/Mitsubishi Tanabe’s
Remicade. Surveyed European rheumatologists expect a particularly
substantial decline by 2013 in the in-class patient share of
Remicade — the only currently marketed intravenous (IV) TNF-alpha
inhibitor.

“However, Remicade’s lost patient share among TNF-alpha
inhibitors will not be fully replaced by uptake of Simponi IV,”
said Decision Resources Analyst Martin Quinn. “Additionally,
considerably more physicians from France, Germany, Spain and the
United Kingdom expect to prescribe subcutaneous Simponi than expect
to prescribe Simponi IV. This trend will be least pronounced in
Italy, where rheumatologists report high patient share for
Remicade.”

The report findings also suggest that the opportunity to gain
patient share is set to increase for recently launched and emerging
biologics with alternative mechanisms of action. These agents
include Bristol-Myers Squibb’s Orencia, Roche/Chugai’s RoActemra
and Genmab/GlaxoSmithKline’s Arzerra. M

‘/>”/>

SOURCE

Related Articles Read More >

UMN artificial blood vessel clinical trial
Minnesota researchers awarded $3.7M grant for artificial, bioengineered blood vessel clinical trial
CeQur Simplicity
CeQur is launching a discreet, convenient ‘wearable insulin pen’
Blackrock's Utah array is a miniature array of electrodes for sensing brain signals
Blackrock Neurotech and Pitt work on first at-home BCI system for remote trials
Engineer inspecting artificial hip joint parts in quality control department in orthopaedic factory
Deburring and finishing for beautiful, functional medical devices

DeviceTalks Weekly.

August 5, 2022
DTW Medtronic's Greg Smith lays out supply chain strategies
See More >

MDO Digital Edition

Digital Edition

Subscribe to Medical Design & Outsourcing. Bookmark, share and interact with the leading medical design engineering magazine today.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
DeviceTalks

DeviceTalks is a conversation among medical technology leaders. It's events, podcasts, webinars and one-on-one exchanges of ideas & insights.

DeviceTalks

New MedTech Resource

Medical Tubing

Enewsletter Subscriptions

Enewsletter Subscriptions

MassDevice

Mass Device

The Medical Device Business Journal. MassDevice is the leading medical device news business journal telling the stories of the devices that save lives.

Visit Website
MDO ad
Medical Design and Outsourcing
  • MassDevice
  • DeviceTalks
  • MedTech100 Index
  • Medical Tubing + Extrusion
  • Medical Design Sourcing
  • Drug Delivery Business News
  • Drug Discovery & Development
  • Pharmaceutical Processing World
  • R&D World
  • About Us/Contact
  • Advertise With Us
  • Subscribe to Print Magazine
  • Subscribe to E-newsletter
  • Attend our Monthly Webinars
  • Listen to our Weekly Podcasts
  • Join our DeviceTalks Tuesdays Discussion

Copyright © 2022 WTWH Media, LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media LLC. Site Map | Privacy Policy | RSS

Search Medical Design & Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • Subscribe to Print Magazine
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech